Literature DB >> 2328029

Long-term immunomodulatory effects of T lymphocyte depletion in patients with systemic sclerosis.

J J Goronzy1, C M Weyand.   

Abstract

We describe 2 patients with rapidly progressing systemic sclerosis that did not respond to conventional therapy, who were treated with a 5-day regimen of T cell-specific antilymphocyte globulin. One patient had deteriorating pulmonary involvement, and the second patient had developed disabling skin disease with multiple ulcers and gangrene. Both patients showed improvement concomitant with almost complete elimination of CD4+ and CD8+ T lymphocytes. Regeneration of peripheral T cells required 60-90 days and was followed by a long-term inversion of the CD4:CD8 ratio. The persistent therapeutic effect in both patients correlated with the lack of CD4+ T cells and the predominance of CD8+ T cells. This suggests a crucial role of T cell immunity in the pathogenesis of systemic sclerosis. In vitro studies of regenerating T cells demonstrated that CD4+ helper/inducer cells were functionally competent. Alterations in the composition of the CD8+ population may explain the prolonged suppression of CD4+ T cells observed during the period of therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328029     DOI: 10.1002/art.1780330408

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

Review 1.  Current therapy of systemic sclerosis (scleroderma).

Authors:  U Müller-Ladner; K Benning; B Lang
Journal:  Clin Investig       Date:  1993-04

2.  HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease.

Authors:  Seth P Epstein; Neha Gadaria-Rathod; Yi Wei; Maureen G Maguire; Penny A Asbell
Journal:  Exp Eye Res       Date:  2013-04-06       Impact factor: 3.467

3.  Fatal exacerbation of paraneoplastic systemic sclerosis after neoadjuvant chemotherapy in a breast cancer patient.

Authors:  Ruby Kochhar; Jay N Umbreit
Journal:  Clin Rheumatol       Date:  2004-04-14       Impact factor: 2.980

4.  Selective targeting of pro-inflammatory Th1 cells by microRNA-148a-specific antagomirs in vivo.

Authors:  Patrick Maschmeyer; Georg Petkau; Francesco Siracusa; Jakob Zimmermann; Franziska Zügel; Anja Andrea Kühl; Katrin Lehmann; Sarah Schimmelpfennig; Melanie Weber; Claudia Haftmann; René Riedel; Markus Bardua; Gitta Anne Heinz; Cam Loan Tran; Bimba Franziska Hoyer; Falk Hiepe; Sebastian Herzog; Jürgen Wittmann; Nikolaus Rajewsky; Fritz Georg Melchers; Hyun-Dong Chang; Andreas Radbruch; Mir-Farzin Mashreghi
Journal:  J Autoimmun       Date:  2017-12-01       Impact factor: 7.094

Review 5.  Human autoimmune diseases are specific antigen-driven T-cell diseases: identification of the antigens.

Authors:  Chris D Platsoucas; Emilia L Oleszak
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.